Medicine for treating pregnancy with hyperthyroidism

Abstract

The invention discloses a medicine for treating pregnancy with hyperthyroidism, for solving the problem of treating hyperthyroidism in pregnancy. The medicine comprises crab grass, ardisiae japonica, aeschynomene indica, trifolium pratense, loofah sponge, allium victorialis, magnolia amoena, bark of himalayan coralbean, lotus leaves, vandenboschia auriculata, fructus cannabis and fried setaria italic. The clinical experiment shows that the medicine has the characteristics of good curative effect and relatively high security when being used for treating pregnancy with hyperthyroidism.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicines, in particular to a medicine for treating pregnancy complicated with hyperthyroidism. Background technique [0002] The incidence of pregnancy complicated hyperthyroidism (pregnancy complicating hyperthyroidism, PCH) is about 0.1% to 0.4%. Among the endocrine diseases in pregnant women, thyroid disease ranks second only to diabetes. PCH is a high-risk disease of pregnancy, which is extremely harmful. The pregnancy loss rate is as high as 26%, and the premature delivery rate is 15%. It is also prone to fetal growth restriction (FGR), and its most important impact on the mother is thyroid storm. Once it occurs, the mortality rate can be as high as 25%, so it is very important to give timely and appropriate treatment to PCH patients during pregnancy. [0003] The vast majority of PCH is Grave's disease, which accounts for more than 85% of all patients with hyperthyroidism. The exact mech...

AI Technical Summary

Problems solved by technology

At the same time, because the existing ATD can pass through the placental barrier, there are hidden dangers to the growth and development of the fetus. For example, excessive ATD will cause fetal hypothyroidism and goiter, which will affect the normal development of the fetus. Therefore, the existing clinical treatment plans mostly advocate pregnancy. The minimum dose of ATD should be applied in the long term, and the FT4 should not exceed 1.4 times the upper limit of normal

Due to the inability to use therapeutic drugs in sufficient quantities, FT4 remains at a high level, so the maternal and infant complications (such as miscarriage, premature delivery, fetal growth retardation, pregnancy-induced hypertension syndrome, etc.) of ATD treatment at this safe dose are not ideally controlled, and breastfeeding The recurrence rate in the early period is as high as 50% to 60%, which affects postpartum breastfeeding.

In addition, if the mother's hyperthyroidism has not been properly treated, neonatal hyperthyroidism will occur in 1 to 3% of the cases, and the mortality rate may reach 10% to 15%.

[0005] In addition, since β-adrenergic blockers can increase uterine muscle tone, resulting in placental dysplasia and fetal intrauterine growth retardation, it should not be used as the drug of choice in hyperthyroidism during pregnancy

For the control of tachycardia associated with PCH, there is currently no better drug